2024
Mechanistic Differences between Torsemide and Furosemide.
Rao V, Cox Z, Ivey-Miranda J, Neville D, Balkcom N, Moreno-Villagomez J, Ramos-Mastache D, Maulion C, Bellumkonda L, Tang W, Collins S, Velazquez E, Mentz R, Wilson F, Turner J, Wilcox C, Ellison D, Fang J, Testani J. Mechanistic Differences between Torsemide and Furosemide. Journal Of The American Society Of Nephrology 2024 PMID: 39196651, DOI: 10.1681/asn.0000000000000481.Peer-Reviewed Original ResearchTorsemide groupDiuretic doseTubular site of actionHigher diuretic dosesDose of furosemideProportion of dosesOral furosemideSite of actionPrescribed doseNeurohormonal activationMechanistic substudyClinical outcomesPharmacodynamic advantagesKidney dysfunctionPharmacodynamic parametersKidney functionRandomized trialsNatriuresisTubular sitesFurosemideTorsemideDoseTRANSFORM-HFPlasma volumeBody weight
2017
Renal tubular resistance is the primary driver for loop diuretic resistance in acute heart failure
Maaten J, Rao VS, Hanberg JS, Wilson F, Bellumkonda L, Assefa M, Broughton J, D'Ambrosi J, Tang W, Damman K, Voors AA, Ellison DH, Testani JM. Renal tubular resistance is the primary driver for loop diuretic resistance in acute heart failure. European Journal Of Heart Failure 2017, 19: 1014-1022. PMID: 28105769, PMCID: PMC6231236, DOI: 10.1002/ejhf.757.Peer-Reviewed Original ResearchConceptsAcute heart failureLoop diuretic resistanceRenal tubular responseDiuretic resistanceDiuretic responseRenal tubulesAHF patientsHeart failureLoop diureticsTubular responseRenal tubular resistanceBumetanide doseEffective decongestionIntravenous bumetanidePoor outcomeUrine collectionTubular resistanceSum of defectsPatient variabilityUrea clearancePatientsCommon barriersDoseClearanceDiuretics
2012
Low Cefepime Concentrations during High Blood and Dialysate Flow Continuous Venovenous Hemodialysis
Wilson FP, Bachhuber MA, Caroff D, Adler R, Fish D, Berns J. Low Cefepime Concentrations during High Blood and Dialysate Flow Continuous Venovenous Hemodialysis. Antimicrobial Agents And Chemotherapy 2012, 56: 2178-2180. PMID: 22290968, PMCID: PMC3318326, DOI: 10.1128/aac.05987-11.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Bacterial AgentsCefepimeCephalosporinsChromatography, High Pressure LiquidFemaleHalf-LifeHemofiltrationHumansKidney Failure, ChronicKidney Tubular Necrosis, AcuteMaleMicrobial Sensitivity TestsMiddle AgedPseudomonas aeruginosaShock, CardiogenicSpectrophotometry, UltravioletYoung Adult